Developer docs
API playgroundTry for free, no card

Search company profiles

SteinCares

Full company profile

uuid000aoap

Namestring
SteinCares
Legal namestring
SteinCares S.A.
Websiteurl
steincares.com
Company typeenum
Private
Founded yearint
1980
Short descriptiontext

SteinCares is a Costa Rica-based specialty healthcare company that licenses, registers, and distributes biosimilars and complex generics across 30 Latin American countries through exclusive partnerships with global biopharmaceutical developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSan José, Costa Rica
HQ citystring
San José
HQ countrystring
Costa Rica
HQ regionstring
Latin America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, biosimilar distribution, pharmaceutical licensing, Latin America healthcare, complex generics
Industry1 code
PRIMARYHLAFAAAO
Hospital Shared Services, GPOs & System Support Organizations
Healthcare & Life Sciences/Healthcare Providers & Systems/Acute Care Hospitals & Health Systems
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biosimilar Licensing and Distribution
TypeLicensing Royalties
Description

SteinCares generates revenue through exclusive licensing agreements to register, commercialize, and distribute biosimilar products across Latin American markets. The company partners with development and manufacturing firms to bring cost-effective treatments to the region.

thepharmaletter.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SteinCares is a Costa Rica-based specialty healthcare company that acquires exclusive rights to register, commercialize, and distribute biosimilars, complex generics, and innovative pharmaceuticals across 30 countries in Latin America. The company leverages strategic licensing agreements with international biopharmaceutical developers (e.g., Shilpa Biologicals, Bio-Thera Solutions) and combines regional regulatory expertise with commercialization and distribution infrastructure to expand patient access to cost-effective specialty medicines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Improved access to specialty medicines across Latin America
+1 more record
Product overview1 text field

SteinCares operates as a specialty healthcare company offering a unified platform for biosimilar medicines across Latin America. The company provides integrated services combining regional regulatory expertise, commercialization capabilities, and distribution infrastructure spanning 30 countries. SteinCares leverages partnerships with biopharmaceutical developers (such as Shilpa Biologicals and Bio-Thera Solutions) to register, commercialize, and distribute biosimilar products, focusing on expanding patient access to cost-effective treatments for chronic inflammatory and other diseases.

Product and service3 records
1Biosimilar Commercialization Platform
CategorySpecialty Pharmaceuticals Distribution
Description

An integrated platform spanning 30 Latin American countries that handles regulatory registration, commercialization, and distribution of biosimilar medicines on behalf of development partners; serves healthcare systems, payers, and patients across the region seeking affordable specialty treatments.

2Dupilumab Biosimilar (IL-4 Antibody)
CategoryBiosimilar Medicines
Description

A proposed biosimilar of dupilumab targeting IL-4 antibody-based treatments for chronic inflammatory diseases; SteinCares holds exclusive rights to register, commercialize, and distribute across Latin America; serves patients with chronic inflammatory conditions and healthcare systems/payers seeking affordable specialty treatments.

3Shilpa Biologicals Biosimilar (Latin America Rights)
CategoryBiosimilar Medicines
Description

A biosimilar developed and manufactured by Shilpa Biologicals in India, with SteinCares holding exclusive rights to register, commercialize, and distribute across 30 Latin American countries; serves healthcare systems, payers, and patients across the region.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Strategic licensing agreement where SteinCares holds exclusive rights to register, commercialize, and distribute a biosimilar across Latin America while Shilpa Biologicals handles product development and manufacturing at its facility in Dharwad, India. The partnership marks Shilpa Biologicals' entry into the Latin American market and combines their biologics development expertise with SteinCares' integrated regional platform spanning 30 countries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Partnership to commercialize a proposed biosimilar of dupilumab for treating chronic inflammatory diseases throughout Latin America. The alliance combines Bio-Thera Solutions' biologics development expertise with SteinCares' regional registration and commercialization capabilities to expand access to IL-4 antibody-based treatments in emerging markets.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Eurofarma
TypeDirect peer
Description

Brazilian-founded multinational pharmaceutical company with deep Latin American presence across generics, branded generics, and biosimilars. Eurofarma is comparable to SteinCares as a major regional specialty/generics platform operating across multiple LATAM markets and pursuing biosimilar partnerships.

TypeDirect peer
Description

Latin American specialty pharmaceutical company focused on oncology, specialty care, and rare diseases, with presence in more than 20 countries. Adium is comparable to SteinCares as a regional specialty pharma commercialization platform that licenses and distributes advanced therapies across LATAM.

TypeDirect peer
Description

Multinational pharmaceutical company headquartered in Jordan/UK with significant presence in MENA, North America, and emerging markets, focused on generics and specialty medicines. Hikma is comparable to SteinCares as a generic/specialty pharma operator with a multi-country emerging-market distribution footprint.

4Laboratorios Pisa
TypeDirect peer
Description

Mexican pharmaceutical company with regional presence focused on generics, biosimilars, and specialty medicines. Laboratorios Pisa is comparable to SteinCares as a LATAM specialty/generics platform serving healthcare systems with cost-effective pharmaceutical products.

TypeBroad incumbent
Description

Israel-based multinational and the world's largest generic drug manufacturer, with a sizable biosimilar portfolio and global commercial reach. Teva is comparable to SteinCares as a global generic/biosimilar leader whose breadth and capital pose a competitive threat to regional intermediaries.

6Sandoz
TypeBroad incumbent
Description

Global leader in generics and biosimilars, spun out of Novartis as a standalone company in 2023, with worldwide commercialization capabilities. Sandoz is comparable to SteinCares as a major biosimilar player whose direct LATAM entry could bypass regional licensing partners.

TypeEmerging player
Description

Indian biopharmaceutical company with a global biosimilar portfolio (insulin, trastuzumab, bevacizumab, etc.) and commercial partnerships in emerging markets. Biocon is comparable to SteinCares as a biosimilar developer that competes with — and often partners with — regional LATAM distributors.

TypeEmerging player
Description

South Korean biosimilar developer (Samsung Biologics/Biogen joint venture) commercializing biosimilars globally through licensing and direct partnerships. Samsung Bioepis is comparable to SteinCares as a biosimilar counterpart that may license to or bypass regional LATAM distributors.

TypeEmerging player
Description

South Korean biopharmaceutical company and one of the world's largest biosimilar manufacturers, with a global commercialization strategy. Celltrion is comparable to SteinCares as a major biosimilar supplier whose LATAM route-to-market choices affect regional distributor economics.

TypeBroad incumbent
Description

US-based generic and specialty pharmaceutical company with global manufacturing and distribution operations, including a growing biosimilar pipeline. Amneal is comparable to SteinCares as a broad generic/specialty pharma player with emerging-market distribution ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SteinCares

Specialty Pharmaceuticalssteincares.com

SteinCares is a Costa Rica-based specialty healthcare company that licenses, registers, and distributes biosimilars and complex generics across 30 Latin American countries through exclusive partnerships with global biopharmaceutical developers.

SteinCares firmographics

Firmographics
Name
SteinCares
Legal name
SteinCares S.A.
Website
https://steincares.com
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
251–500 employees
Short description
SteinCares is a Costa Rica-based specialty healthcare company that licenses, registers, and distributes biosimilars and complex generics across 30 Latin American countries through exclusive partnerships with global biopharmaceutical developers.
Ownership category
akta.pro rank

SteinCares industry classification

Industry
Product category
Specialty Pharmaceuticals
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAFAAAO
Hospital Shared Services, GPOs & System Support Organizations
Healthcare & Life Sciences/Healthcare Providers & Systems/Acute Care Hospitals & Health Systems

Keywords

  • Specialty pharmaceuticals
  • Biosimilar distribution
  • Pharmaceutical licensing
  • Latin America healthcare
  • Complex generics

Where SteinCares is headquartered

Location

Headquarters

HQ city
San José
HQ country
Costa Rica
HQ region
Latin America

Offices1 record

Markets served

SteinCares business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Biosimilar Licensing and Distribution: SteinCares generates revenue through exclusive licensing agreements to register, commercialize, and distribute biosimilar products across Latin American markets. The company partners with development and manufacturing firms to bring cost-effective treatments to the region.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

SteinCares product offering

Product offering

Core offering

SteinCares is a Costa Rica-based specialty healthcare company that acquires exclusive rights to register, commercialize, and distribute biosimilars, complex generics, and innovative pharmaceuticals across 30 countries in Latin America. The company leverages strategic licensing agreements with international biopharmaceutical developers (e.g., Shilpa Biologicals, Bio-Thera Solutions) and combines regional regulatory expertise with commercialization and distribution infrastructure to expand patient access to cost-effective specialty medicines.

Product overview

SteinCares operates as a specialty healthcare company offering a unified platform for biosimilar medicines across Latin America. The company provides integrated services combining regional regulatory expertise, commercialization capabilities, and distribution infrastructure spanning 30 countries. SteinCares leverages partnerships with biopharmaceutical developers (such as Shilpa Biologicals and Bio-Thera Solutions) to register, commercialize, and distribute biosimilar products, focusing on expanding patient access to cost-effective treatments for chronic inflammatory and other diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biosimilar Commercialization Platform An integrated platform spanning 30 Latin American countries that handles regulatory registration, commercialization, and distribution of biosimilar medicines on behalf of development partners; serves healthcare systems, payers, and patients across the region seeking affordable specialty treatments.
  • Dupilumab Biosimilar (IL-4 Antibody) A proposed biosimilar of dupilumab targeting IL-4 antibody-based treatments for chronic inflammatory diseases; SteinCares holds exclusive rights to register, commercialize, and distribute across Latin America; serves patients with chronic inflammatory conditions and healthcare systems/payers seeking affordable specialty treatments.
  • Shilpa Biologicals Biosimilar (Latin America Rights) A biosimilar developed and manufactured by Shilpa Biologicals in India, with SteinCares holding exclusive rights to register, commercialize, and distribute across 30 Latin American countries; serves healthcare systems, payers, and patients across the region.

Quantifiable outcome

  • Improved access to specialty medicines across Latin America
  • +1 more outcomes

Companies that use SteinCares

Customer profile

Segments2 records

Ideal customer profiles2 records

SteinCares technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

SteinCares partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Shilpa BiologicalscoreStrategic or Co-development Partner · 25 February 2026Strategic licensing agreement where SteinCares holds exclusive rights to register, commercialize, and distribute a biosimilar across Latin America while Shilpa Biologicals handles product development and manufacturing at its facility in Dharwad, India. The partnership marks Shilpa Biologicals' entry into the Latin American market and combines their biologics development expertise with SteinCares' integrated regional platform spanning 30 countries.
  • Bio-Thera Solutions Ltd.coreStrategic or Co-development Partner · 1 June 2025Partnership to commercialize a proposed biosimilar of dupilumab for treating chronic inflammatory diseases throughout Latin America. The alliance combines Bio-Thera Solutions' biologics development expertise with SteinCares' regional registration and commercialization capabilities to expand access to IL-4 antibody-based treatments in emerging markets.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

SteinCares competitors and assessment

Company assessment

Direct peers

  • Eurofarma: Brazilian-founded multinational pharmaceutical company with deep Latin American presence across generics, branded generics, and biosimilars. Eurofarma is comparable to SteinCares as a major regional specialty/generics platform operating across multiple LATAM markets and pursuing biosimilar partnerships.
  • Adium: Latin American specialty pharmaceutical company focused on oncology, specialty care, and rare diseases, with presence in more than 20 countries. Adium is comparable to SteinCares as a regional specialty pharma commercialization platform that licenses and distributes advanced therapies across LATAM.
  • Hikma Pharmaceuticals: Multinational pharmaceutical company headquartered in Jordan/UK with significant presence in MENA, North America, and emerging markets, focused on generics and specialty medicines. Hikma is comparable to SteinCares as a generic/specialty pharma operator with a multi-country emerging-market distribution footprint.
  • Laboratorios Pisa: Mexican pharmaceutical company with regional presence focused on generics, biosimilars, and specialty medicines. Laboratorios Pisa is comparable to SteinCares as a LATAM specialty/generics platform serving healthcare systems with cost-effective pharmaceutical products.

Broad incumbents

  • Teva Pharmaceutical Industries: Israel-based multinational and the world's largest generic drug manufacturer, with a sizable biosimilar portfolio and global commercial reach. Teva is comparable to SteinCares as a global generic/biosimilar leader whose breadth and capital pose a competitive threat to regional intermediaries.
  • Sandoz: Global leader in generics and biosimilars, spun out of Novartis as a standalone company in 2023, with worldwide commercialization capabilities. Sandoz is comparable to SteinCares as a major biosimilar player whose direct LATAM entry could bypass regional licensing partners.
  • Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical company with global manufacturing and distribution operations, including a growing biosimilar pipeline. Amneal is comparable to SteinCares as a broad generic/specialty pharma player with emerging-market distribution ambitions.

Emerging players

  • Biocon: Indian biopharmaceutical company with a global biosimilar portfolio (insulin, trastuzumab, bevacizumab, etc.) and commercial partnerships in emerging markets. Biocon is comparable to SteinCares as a biosimilar developer that competes with — and often partners with — regional LATAM distributors.
  • Samsung Bioepis: South Korean biosimilar developer (Samsung Biologics/Biogen joint venture) commercializing biosimilars globally through licensing and direct partnerships. Samsung Bioepis is comparable to SteinCares as a biosimilar counterpart that may license to or bypass regional LATAM distributors.
  • Celltrion: South Korean biopharmaceutical company and one of the world's largest biosimilar manufacturers, with a global commercialization strategy. Celltrion is comparable to SteinCares as a major biosimilar supplier whose LATAM route-to-market choices affect regional distributor economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

SteinCares social profiles

Digital presence

SteinCares financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SteinCares leadership team

Management profile

Number of profiles

Profiles1 record

SteinCares funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SteinCares M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SteinCares

What does SteinCares do?

SteinCares is a Costa Rica-based specialty healthcare company that acquires exclusive rights to register, commercialize, and distribute biosimilars, complex generics, and innovative pharmaceuticals across 30 countries in Latin America. The company leverages strategic licensing agreements with international biopharmaceutical developers (e.g., Shilpa Biologicals, Bio-Thera Solutions) and combines regional regulatory expertise with commercialization and distribution infrastructure to expand patient access to cost-effective specialty medicines.

Is SteinCares a public or private company?

SteinCares is a private company. It is classified as private equity controlled and is currently operating.

When was SteinCares founded?

SteinCares was founded in 1980. It employs 251 to 500 people.

Where is SteinCares based?

SteinCares is headquartered in San José, Costa Rica, in the Latin America region.

How does SteinCares make money?

One revenue line is on record: biosimilar Licensing and Distribution.

Who are SteinCares's main competitors?

Direct peers on record are Eurofarma, Adium, Hikma Pharmaceuticals and Laboratorios Pisa. Broad incumbents are Teva Pharmaceutical Industries, Sandoz and Amneal Pharmaceuticals. Emerging players are Biocon, Samsung Bioepis and Celltrion.

Does SteinCares have an API?

No public API is recorded for SteinCares.

What industry is SteinCares in?

SteinCares's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAFAAAO, Hospital Shared Services, GPOs & System Support Organizations. Its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NasdaqSanthera, SteinCares Sign Deal To Expand AGAMREE Access Across 31 CountriesSanthera Pharmaceuticals and SteinCares signed an exclusive agreement to distribute AGAMREE for Duchenne muscular dystrophy across 31 countries in Latin America and the Caribbean. The rollout initially targets Brazil, with expansion into other markets in parallel. Santhera will receive a percentage of net sales, though the percentage was not disclosed.Business & FinancialSanthera Signs Distribution Agreement With Steincares For AGAMREE® (Vamorolone) In 31 Countries Across Latin America And The CaribbeanSanthera signed a distribution agreement with SteinCares to bring AGAMREE (vamorolone) to 31 Latin American and Caribbean countries, including Brazil, Colombia, and Argentina. The launch will initially focus on Brazil, where SteinCares will pursue regulatory registration and access through exceptional importation pathways. Santhera will receive a percentage of net sales.FinancialContent Business PageSanthera Signs Distribution Agreement with SteinCares for AGAMREE® (Vamorolone) in 31 countries across Latin America and the CaribbeanSanthera Pharmaceuticals signed an exclusive distribution agreement with SteinCares for AGAMREE (vamorolone) in 31 Latin American and Caribbean countries. The launch will initially focus on Brazil, where SteinCares will pursue regulatory registration and access via exceptional importation pathways. Santhera will receive a percentage of net sales.GlobeNewswireSanthera Signs Distribution Agreement with SteinCares for AGAMREE® (Vamorolone) in 31 countries across Latin America and the CaribbeanSanthera Pharmaceuticals signed an exclusive distribution agreement with SteinCares for AGAMREE (vamorolone) in 31 Latin American and Caribbean countries. The launch will initially focus on Brazil, where SteinCares will pursue regulatory registration and access via exceptional importation pathways. Santhera will receive a percentage of net sales.GlobeNewswireSanthera unterzeichnet Vertriebsvereinbarung mit SteinCares für AGAMREE® (Vamorolon) in 31 Ländern Lateinamerikas und der KaribikSanthera Pharmaceuticals signed an exclusive distribution agreement with SteinCares for AGAMREE (Vamorolon) in 31 Latin American and Caribbean countries. The deal targets about 15,000 people with Duchenne muscular dystrophy, with Brazil as the initial market. Santhera will receive a percentage of net sales.openPR.comOverview of Segmentation, Market Dynamics, and Competitive Landscape in the Interleukin (IL)-4 Antibody MarketThe Business Research Company published an overview of the interleukin (IL)-4 antibody market, projecting it will reach $3.5 billion by 2030 with an 8.5% compound annual growth rate, driven by increasing demand for precision immunomodulators and expanded autoimmune disease research. In June 2025, Bio-Thera Solutions Ltd. of China formed a partnership with SteinCares S.A. to commercialize a proposed biosimilar of dupilumab for treating chronic inflammatory diseases throughout Latin America. The alliance combines Bio-Thera Solutions' biologics development expertise with SteinCares' regional registration and commercialization capabilities to expand access to IL-4 antibody-based treatments in emerging markets.The Pharma LetterSteinCares, Shilpa strike Latin America biosimilar licensing pactSteinCares, a Costa Rica-based specialty healthcare company, has signed a licensing agreement with India’s Shilpa Biologicals (part of Shilpa Medicare) to commercialize a biosimilar across Latin America. The agreement expands Shilpa Medicare's geographic footprint into the Latin American market through a regional commercialization partner.PharmiWeb.comSteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin AmericaSteinCares, a specialty healthcare company in Latin America, and Shilpa Biologicals, a biopharmaceutical subsidiary of Shilpa Medicare Limited, have entered a strategic licensing agreement to commercialize a biosimilar across Latin America. Under the agreement, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar while Shilpa Biologicals will handle product development and long-term commercial manufacturing from its facility in Dharwad, India. The partnership marks Shilpa Biologicals' entry into the Latin American market and reinforces SteinCares' leadership position in the regional biosimilars sector.PR NewswireSteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin AmericaSteinCares and Shilpa Biologicals announced a licensing agreement to expand biosimilar access across Latin America, with SteinCares holding rights to register, commercialize, and distribute the biosimilar while Shilpa Biologicals manages product development and manufacturing in India. The partnership marks Shilpa Biologicals' entry into the Latin American market, reinforcing SteinCares' leadership in biosimilars in the region. This collaboration aims to broaden patient access to cost-effective treatments and create future international partnerships.PR NewswireSteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin AmericaSteinCares and Shilpa Biologicals have announced a strategic licensing agreement to commercialize a biosimilar across Latin America, with SteinCares holding exclusive rights to register, commercialize, and distribute the product while Shilpa Biologicals handles development and manufacturing from its Dharwad, India facility. The partnership marks Shilpa Biologicals' entry into the Latin American market and combines SBPL's biologics development and manufacturing capabilities with SteinCares' integrated regional platform spanning 30 countries. Both companies describe the collaboration as a strategic move to expand patient access to cost-effective treatments and to create a platform for future biosimilars partnerships in key international markets.